Abstract
We compared the in vivo and in vitro activities of CS-940, a new fluoroquinolone, with those of a group of other drugs. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.
Full Text
The Full Text of this article is available as a PDF (192.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Biedenbach D. J., Sutton L. D., Jones R. N. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325–2330. doi: 10.1128/aac.39.10.2325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fujimaki K., Noumi T., Saikawa I., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827–833. doi: 10.1128/aac.32.6.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Masuda N., Takahashi Y., Otsuki M., Ibuki E., Miyoshi H., Nishino T. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother. 1996 May;40(5):1201–1207. doi: 10.1128/aac.40.5.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsumoto M., Kojima K., Nagano H., Matsubara S., Yokota T. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation. Antimicrob Agents Chemother. 1992 Aug;36(8):1715–1719. doi: 10.1128/aac.36.8.1715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miyazaki S., Nunoya T., Matsumoto T., Tateda K., Yamaguchi K. New murine model of bronchopneumonia due to cell-bound Haemophilus influenzae. J Infect Dis. 1997 Jan;175(1):205–209. doi: 10.1093/infdis/175.1.205. [DOI] [PubMed] [Google Scholar]
- Tateda K., Takashima K., Miyazaki H., Matsumoto T., Hatori T., Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother. 1996 Jun;40(6):1520–1525. doi: 10.1128/aac.40.6.1520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]